Management of cancer of the parotid gland

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 10, Issue 2, 2002, Pages 134-144

  Hollander, Lawrence ^a,b   Cunningham, Myles P ^a,c  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b St Francis Hospital   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CONTROL; CANCER CYTODIAGNOSIS; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; HISTOPATHOLOGY; HUMAN; METASTASIS; NECK DISSECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PAROTID GLAND CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT FAILURE;

EID: 0036204435     PISSN: 10689508     EISSN: None     Source Type: Journal    
DOI: 10.1097/00020840-200204000-00013     Document Type: Review

References (136)

1. Primary parotid malignancies: A clinical and pathologic review
2. Salivary glands
3. Surgical outcome in malignant parotid tumors
4. The development of a prognostic score for patients with parotid carcinoma
5. Prudent management of the mid-cheek mass: Revisiting the accessory parotid gland tumor
6. Malignant epithelial tumors
7. Management of malignant tumors of the salivary glands
8. Signs and symptoms of malignant parotid tumors: An objective assessment
9. Salivary gland carcinomas: Prognostic factors
10. Surgical management of the facial nerve in the presence of malignancy about the face
11. Cancer of the parotid gland: A clinicopathologic study of 288 primary cases
12. Prognostic variables in parotid gland cancer
13. Malignant parotid tumors in 110 consecutive patients: Treatment results and prognosis
14. Malignant epithelial parotid gland tumors: Analysis and results in 65 previously untreated patients
15. Limitations of magnetic resonance imaging in the evaluation of perineural tumor spread causing facial nerve paralysis
16. False-negative magnetic resonance imaging in the evaluation of facial nerve paralysis
17. Introduction
18. Tissue effects of salivary gland fine-needle aspiration: Does this procedure preclude accurate histologic diagnosis?
19. The surgical pathology of salivary gland neoplasms
20. Utility of immediate on-site cytopathologic procurement and evaluation in fine needle aspiration biopsy of head and neck masses
21. The relative value of fine-needle aspiration and imaging in the preoperative evaluation of parotid masses
22. Fine-needle aspiration of 154 parotid masses with histologic correlation: Ten-year experience at the University of Texas M. D. Anderson Cancer Center
23. Fine needle aspiration biopsy (FNAB) for lesions of the salivary glands
24. Management of malignant salivary gland tumors
25. Major salivary gland imaging
26. Identification of the intraparotid facial nerve on magnetic resonance imaging
27. Consecutive imaging of the facial nerve using high-resolution magnetic resonance imaging
28. Microanatomy of the excised human spinal cord and the cervicomedullary junction examined with high-resolution MR imaging at 9.4 Tesla
29. AJCC stage groupings for head and neck cancer: Should we look at alternatives? A report of the head and neck sites task force
30. Carcinoma of the major salivary glands treated by surgery or surgery plus postoperative radiotherapy
31. Carcinoma of major salivary glands: Recent trends
32. Risk factors for distant metastases from carcinoma of the parotid gland
33. What do we mean by validating a prognostic model?
34. Evaluation of the validity of the 1997 International Union Against Cancer TNM classification of major salivary gland carcinoma
35. Salivary gland tumors
36. Facial nerve rehabilitation after radical parotidectomy
37. An analysis of facial nerve function in irradiated and unirradiated facial nerve grafts
38. Facial nerve grading system
39. Effect of radiation therapy on facial nerve cable autografts
40. The indications for elective treatment of the neck in cancer of the major salivary glands
41. Malignant tumors of major salivary gland origin: A matched-pair analysis of the role of combined surgery and postoperative radiotherapy
42. Neck dissection in the treatment of cancer of major salivary glands
43. Management of clinically negative cervical lymph nodes in patients with malignant neoplasms of the parotid gland
44. Malignant epithelial parotid tumors: A rational treatment policy
45. Management of the neck in parotid carcinoma
46. Predicting occult lymph node metastasis in parotid cancer
47. Treatment of malignant neoplasms of the parotid gland
48. Multi-variate analysis of risk factors for neck metastases in surgically treated parotid carcinomas
49. Accuracy of frozen section in the evaluation of salivary tumors
50. The world health organization's histologic classification of salivary gland tumors: A commentary on the second edition
51. Acinic cell carcinoma of the salivary glands: A review of 20 new cases
52. Epithelial-myoepithelial carcinoma of salivary gland with metastasis to lung: Report of a case and review of the literature
53. Epithelial-myoepithelial carcinoma of the salivary glands: A study of 22 cases
54. Epithelial-myoepithelial carcinoma of the salivary gland: A low grade malignant neoplasm? Report of two cases and review of the literature
55. Mucoepidermoid carcinoma: A clinicopathologic study of 80 patients with special reference to histologic grading
56. Low grade salivary duct carcinoma: A distinctive variant with a low grade histology and a predominant intraductal growth pattern
57. Salivary duct carcinoma: An unusual case of long-term evolution
58. Hyalinizing clear cell carcinoma of salivary gland
59. Hyalinizing clear cell carcinoma of salivary origin
60. A rare tumor of salivary gland origin: Hyalinizing clear cell carcinoma
61. Hyalinizing clear cell carcinoma of the oral cavity and of the parotid gland
62. Primary chondrosarcoma arising in the parotid gland
63. Oncocytic mucoepidermoid carcinoma of the parotid gland: Report of a case with DNA ploidy analysis and review of the literature
64. Histogenesis of salivary gland neoplasms
65. Histologic localization of plag 1 (pleomorphic adenoma gene 1) in pleomorphic adenoma of the salivary gland: Cytogenetic evidence of common origin of phenotypically diverse cells
66. Staging of salivary gland neoplasms: Role of histopathologic and molecular factors
67. Mucoepidermoid carcinoma of the major salivary glands: Clinical and histopathologic analysis of 234 cases with evaluation of grading criteria
68. Histocytologic grading of mucoepidermoid carcinoma of major salivary glands in prognosis and survival: A clinicopathologic and flow cytometric investigation
69. Mucoepidermoid carcinoma of salivary gland origin: Classification, clinical-pathologic correlation, and results of treatment
70. Mucoepidermoid carcinoma of salivary gland origin: A clinicopathologic study of 367 cases
71. Mucoepidermoid carcinoma of salivary glands: A study of 69 cases with special attention to histologic grading
72. Histopathologic grading of salivary gland neoplasms, I: Mucoepidermoid carcinomas
73. Histopathologic grading of salivary gland neoplasms, II: Acinic cell carcinomas
74. National Cancer Data Base report on cancer of the head and neck: Acinic cell carcinoma
75. Adenoid cystic carcinomas arising in salivary glands: A correlation of histologic features and clinical course
76. Histologic grading of adenoid cystic carcinoma of the salivary glands
77. Histopathologic grading of salivary gland neoplasms, III: Adenoid cystic carcinomas
78. Stage means more than grade in adenoid cystic carcinoma
79. Tumor-doubling time and onset of pulmonary metastasis from adenoid cystic carcinoma of the salivary gland
80. Immunohistochemical evaluation with Ki-67: An application to salivary gland tumors
81. Expression of p53 tumor suppressor gene in adenoid cystic and mucoepidermoid carcinomas of the salivary glands
82. High correlation with survival of proliferating cell nuclear antigen expression in mucoepidermoid carcinoma of the parotid gland
83. Proliferating cell nuclear antigen expression in mucoepidermold carcinoma of salivary glands
84. Proliferating cell nuclear antigen and c-erbB-2 oncoprotein expression in adenoid cystic carcinomas of the salivary glands
85. Enhancing effects of fibroblast growth factor on the proliferation of salivary gland carcinoma cells and salivary gland carcinogenesis
86. Low p53 protein expression in salivary gland tumors compared with lung carcinomas
87. p53 oncoprotein expression in parotid gland carcinoma is associated with clinical outcome
88. Characterization of AMC-HN-9, a cell line established from an undifferentiated carcinoma of the parotid gland: Expression of alpha6beta4 with the absence of BP180 and 230
89. Reduced E-cadherin expression correlates with unfavorable prognosis in adenoid cystic carcinoma of salivary glands of the oral cavity
90. Carcinoma of the major and minor salivary glands: Analysis of treatment results and sites and causes of failures
91. Postoperative radiation therapy for major salivary gland malignancies
92. Impact of local radiation in the management of salivary gland carcinomas
93. Salivary gland malignant neoplasms: Treatment and prognosis
94. Fast neutron radiotherapy for inoperable salivary gland tumors: Is it the treatment of choice?
95. The role of fast neutron radiation therapy in the management of advanced salivary gland malignant neoplasms
96. Neutron versus photon irradiation for unresectable salivary gland tumors: Final report of an RTOG-MRC randomized clinical trial
97. European results in neutron therapy of malignant salivary gland tumors
98. Neutron therapy in malignant salivary gland tumors: Results at European centers
99. Neutron radiotherapy for the treatment of locally advanced major salivary gland tumors
100. Radiotherapy for advanced adenoid cystic carcinoma: Neutrons, photons or mixed beam?
101. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies
102. Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma
103. Treatment of malignant tumors in the parotid glands
104. Incidence and survival of malignant parotid tumors in the West Midlands region 1977-1986
105. Prognostic variables in malignant epithelial tumors of the parotid
106. Clinico-pathologic and treatment-related factors influencing survival in parotid cancer
107. Distant metastases from salivary glands cancer
108. Treatment of carcinoma of the parotid gland: The results of a multicenter study
109. Evaluation of the newly updated TNM classification of head and neck carcinoma with data from 3247 patients
110. Parotid gland carcinoma: 1987 and 1997 UICC T classifications compared for prognostic accuracy at 5 years
111. Prognostic scoring of patients with parotid carcinoma: External validation using the 1985-1994 NWHHT database
112. Evaluation of 242 consecutive parotidectomies performed for benign and malignant disease
113. Use of a parotid fascia flap to prevent postoperative fistula
114. A pilot study evaluating the treatment of postparotidectomy sialoceles with botulinum toxin type A
115. Frey's syndrome after parotidectomy: A retrospective and prospective analysis
116. Frey's syndrome: Treatment with botulinum toxin
117. Botulinum toxin treatment for symptomatic Frey's syndrome
118. Frey syndrome: Treatment with type A botulinum toxin
119. Recurrent gustatory sweating (Frey syndrome) after intracutaneous injection of botulinum toxin type A: Incidence, management, and outcome
120. The fallacy of preventing Frey syndrome during parotidectomy
121. Frey's syndrome and parotid surgery
122. Frey's syndrome following parotidectomy: Prevention using a rotation sternocleidomastoid muscle flap
123. Parotid surgery and Frey syndrome
124. Prophylaxis against Frey's syndrome in parotid surgery
125. Prevention of Frey syndrome during parotidectomy
126. Quality of life after great auricular nerve sacrifice during parotidectomy
127. Cerebral radionecrosis following the treatment of parotid tumors: A case report and review of the literature
128. Salivary flow dynamics after parotid surgery: A preliminary report
129. Late effects of radiotherapy on hearing
130. Sensori-neural hearing loss in patients treated with irradiation for nasopharyngeal carcinoma
131. A prospective longitudinal study on radiation-induced hearing loss
132. Salivary neoplasms: Overview of a 35-year experience with 2,807 patients
133. Carcinoma of the parotid gland: Analysis of treatment results and patterns of failure after combined surgery and radiation therapy